Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, 吳銘芳, 陳育民, 劉敏, 彭汪嘉康, 李壽東, 雷永耀

Research output: Contribution to journalArticle

Abstract

Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
Original languageEnglish
Pages (from-to)255-262
Number of pages8
Journal放射治療與腫瘤學
Volume1
Issue number3
DOIs
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Stomach Neoplasms
Drug Therapy
Cisplatin
Nasopharyngeal Neoplasms
Mucositis
Leukopenia
Intravenous Infusions
Therapeutics
Survival

Keywords

  • Cisplatin
  • 5-Fluorouracil
  • 頑固性胃癌
  • leucovorin
  • Fluorouracil

Cite this

陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, ... 雷永耀 (1994). Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. 放射治療與腫瘤學, 1(3), 255-262. https://doi.org/10.6316/TRO/199401(3)255

Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. / 陳榮楷; 吳秋文; 林增熙; 季匡華; 趙毅; 黃以信; 吳銘芳; 陳育民; 劉敏; 彭汪嘉康; 李壽東; 雷永耀.

In: 放射治療與腫瘤學, Vol. 1, No. 3, 1994, p. 255-262.

Research output: Contribution to journalArticle

陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, 吳銘芳, 陳育民, 劉敏, 彭汪嘉康, 李壽東 & 雷永耀 1994, 'Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients', 放射治療與腫瘤學, vol. 1, no. 3, pp. 255-262. https://doi.org/10.6316/TRO/199401(3)255
陳榮楷 ; 吳秋文 ; 林增熙 ; 季匡華 ; 趙毅 ; 黃以信 ; 吳銘芳 ; 陳育民 ; 劉敏 ; 彭汪嘉康 ; 李壽東 ; 雷永耀. / Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. In: 放射治療與腫瘤學. 1994 ; Vol. 1, No. 3. pp. 255-262.
@article{bde3db3a0d6746a9ab3ea37a1dfbd659,
title = "Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients",
abstract = "Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27{\%}. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.",
keywords = "Cisplatin, 5-Fluorouracil, 頑固性胃癌, leucovorin, Fluorouracil, Cisplatin, 5-Fluorouracil, Leucovorin, Refractory Gastric Cancer, Fluorouracil",
author = "陳榮楷 and 吳秋文 and 林增熙 and 季匡華 and 趙毅 and 黃以信 and 吳銘芳 and 陳育民 and 劉敏 and 彭汪嘉康 and 李壽東 and 雷永耀",
year = "1994",
doi = "10.6316/TRO/199401(3)255",
language = "English",
volume = "1",
pages = "255--262",
journal = "放射治療與腫瘤學",
issn = "1023-988x",
publisher = "台灣放射腫瘤學會",
number = "3",

}

TY - JOUR

T1 - Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients

AU - 陳榮楷, null

AU - 吳秋文, null

AU - 林增熙, null

AU - 季匡華, null

AU - 趙毅, null

AU - 黃以信, null

AU - 吳銘芳, null

AU - 陳育民, null

AU - 劉敏, null

AU - 彭汪嘉康, null

AU - 李壽東, null

AU - 雷永耀, null

PY - 1994

Y1 - 1994

N2 - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

AB - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.

KW - Cisplatin

KW - 5-Fluorouracil

KW - 頑固性胃癌

KW - leucovorin

KW - Fluorouracil

KW - Cisplatin

KW - 5-Fluorouracil

KW - Leucovorin

KW - Refractory Gastric Cancer

KW - Fluorouracil

U2 - 10.6316/TRO/199401(3)255

DO - 10.6316/TRO/199401(3)255

M3 - Article

VL - 1

SP - 255

EP - 262

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

SN - 1023-988x

IS - 3

ER -